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ABSTRACT 
Background: Psychological factors are recognised as influencing the outcome of spinal 
cord stimulation (SCS) although there is currently no consensus as to which factors impact 
upon SCS efficacy. 
Objective: To identify psychological characteristics that may impact on the efficacy of SCS. 
Design: Prospective cohort study. 
Setting: Single secondary care centre in Dudley, United Kingdom. 
Patients: Seventy-five patients were initially recruited and 56 patients (31 female and 25 
male) were followed-up for 12-months. 
Intervention: SCS for the management of chronic non-cancer pain. 
Main outcome measures: Outcome measures assessed at baseline, six-months and 12-
months following SCS implantation included the visual analogue scale (VAS), Oswestry 
disability index (ODI), hospital anxiety and depression (HAD) scale and the pain coping 
strategies questionnaire (PCSQ). 
Results: Statistically significant improvements were observed for the VAS (p < 0.001), ODI 
(p = 0.011), anxiety (p = 0.042) and depression (p = 0.010) in the HAD scale and for the 
subscales reinterpreting pain sensation (p = 0.018), control over pain (p = 0.001) and ability 
to decrease pain (p < 0.001) of the PCSQ. We observed that depression and autonomous 
coping (control over pain, ability to reduce pain and catastrophising) may impact on sensory 
aspects such as pain intensity and disability scores affecting the outcome of SCS treatment. 
Age at time of implant and duration of pain prior to implant were also found to impact upon 
SCS efficacy. 
Conclusions: This study demonstrates that psychological aspects such as depression and 
autonomous coping may impact on SCS treatment. Addressing these issues prior to SCS 
implantation may improve SCS long-term outcome. 
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INTRODUCTION 
One in five adults (19%) in Europe suffers from chronic pain and over one third of European 
households have at least one chronic or acute pain sufferer (1). Successful treatment 
outcomes are difficult to achieve for chronic pain, causing a great impact on an individual’s 
health, healthcare services and society (2). Spinal cord stimulation (SCS), a treatment for 
chronic pain has been in use since 1967 (3). The SCS electrodes are connected to a pulse 
generator and programmed in anode and cathode combinations to create an electric field 
stimulating the dorsal root and dorsal column fibres in the spinal cord (4). It has been 
suggested that stimulation in this area results in supra-spinal mechanisms, reduced activity 
in the ascending pain pathway (spinothalamic tract) and increased activity in the descending 
antinociceptive pathway (5). Animal studies have shown inhibition of hyperexcitatory actions 
in the dorsal horn and increased levels of GABA released (6). SCS is an expensive and 
invasive therapy; therefore, careful selection for suitability is imperative. A trial period usually 
takes place in most centres prior to SCS implantation to investigate the efficacy of the 
treatment based on pain reduction. Although a successful trial may be achieved initially this 
does not appear to guarantee long-term success. Loss of analgesia can be experienced 
after 12-24 months (7,8). 
Reduced efficacy of SCS may be attributed to technical factors, resulting in loss of target 
area paraesthesia and analgesic efficacy (8). More recently, it has been suggested that the 
impact of psychological factors should be taken into consideration when investigating SCS 
efficacy (9,10). Specific cognitions and methods of coping are understood to interact with the 
pain experience, impacting on the response to pain and subsequent response to treatment 
(11). A recent systematic review observed a lack of consistent evidence to suggest any 
particular psychological factors linked with SCS efficacy (12). Depression was suggested by 
the majority of the studies included in this review as a possible impacting factor; however it 
was concluded that successful treatment could modify the level of depression if it was a 
state in reaction to the pain rather than a trait characteristic. The most common 
psychological factor associated with the onset and continuation of chronic pain is 
catastrophising, alongside a lack of perceived internal control (13-16). It can therefore be 
hypothesised that certain psychological factors, specifically coping strategies may interact 
with the experience of pain and response to SCS. The aim of this prospective study was to 
identify psychological characteristics that may impact on the efficacy of SCS. 
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METHODS 
Participants 
Participants over 18 years of age, with chronic neuropathic pain were recruited for this 
prospective, longitudinal, cohort study following assessment by a multidisciplinary team and 
referral for SCS trial. The multidisciplinary team comprises of a pain consultant, 
physiotherapist and a clinical psychologist to evaluate the different facets of pain and to 
determine patient suitability for SCS according to NICE TA159 (17). Patients are excluded 
on the grounds of being medically unfit for implant surgery, having unrealistic expectations of 
the treatment, lack of comprehension and unrealistic beliefs surrounding their pain. Prior to 
full implantation of the IPG (implantable pulse generator), under local anaesthesia with 
sedation, the SCS electrodes are implanted percutaneously and positioned to obtain 
maximal paraesthetic coverage of the painful area. Electrical parameters are set to obtain 
maximal pain relief and trialled for one week. During the trial period if less than 50% pain 
relief is reported the electrical parameters are altered to try to achieve this level of pain 
reduction. If more than 50% pain relief is reported consistently at the end of the trial week 
the patient proceeds to have a fully implanted SCS. If less than 50% pain relief is reported, 
the leads are removed. 
 
The study was explained and written informed consent was obtained from all participants. 
The patients completed questionnaires and rated their pain at baseline (one week prior to 
SCS trial), six-months and 12-months following SCS implantation. All data were collected 
during routine follow-up appointments. Ethical approval was granted by Birmingham, East, 
North and Solihull Research Ethics Committee (REC reference: 08/H1206/183). 
 
Seventy-five consecutive patients were initially recruited to participate in the study. 
Diagnoses comprised failed back surgery syndrome (42.6%), complex regional pain 
syndrome (33.3%) and other (24.1%) which included for example arachnoiditis and 
coccydynia. Seven of the participants (9.3%) obtained less than 50% pain reduction during 
SCS trial despite adequate topographical mapping and according to current 
recommendations were not implanted (17). Twelve participants were lost to follow-up within 
one year following implantation (16%). A total of 56 patients were included in the final 
analysis. 
 
Sensory and psychological measures 
Assessments were carried out at baseline (one week prior to SCS trial), six-months and 12-
months following SCS implantation. Participants were asked to rate their average pain 
intensity on a 100 mm horizontal visual analogue scale (VAS) (18). The VAS has been 
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shown to be a reliable and valid measure of subjective phenomena including chronic pain 
(18-20). Clinical changes were calculated from the VAS scores measured at baseline and 
after 12-months of SCS implantation (21). Clinically important changes were classified in 
accordance with a consensus statement that established a 10-20% decrease as minimally 
important, ≥30% as moderately important and ≥ 50% as a substantial change (22). 
 
The Oswestry Disability Index (ODI) was used to assess the level of pain interference with 
various activities of daily living. The ODI is a valid measure of condition-specific disability 
(23). The ODI consists of 10 items/activities with 6 levels (range 0-5). This questionnaire has 
been recommended as a tool to measure pain related disability when considering areas 
other than and including low back pain (24). ODI scores between 0-20% were considered as 
minimal disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 
and 81-100% as bed-bound or exaggerating their symptoms (23). A change from baseline of 
10.5 points was considered as a minimal clinically important difference (25). 
 
Anxiety and depression were measured using the Hospital Anxiety and Depression (HAD) 
scale (26). The HAD consists of 14 items allowing the patient to select how frequently they 
experience a particular situation (e.g. I feel tense and wound up: most of the time/ a lot of the 
time/ from time to time/ not at all). The maximum score for each subscale (anxiety and 
depression) is 21. Scores can be divided into four ranges representing the severity of 
symptoms: normal (0-7), borderline (8-10), abnormal (≥11). The depression items of this 
scale focus on the anhedonic state, therefore avoiding the measurement of depression 
affected by a physical condition. The HAD has been considered a sensitive measure and 
suitable for assessing anxiety and depression in primary care patients and the general 
population (27). Internal consistency of the HAD scale has been examined with reports of 
Cronbach’s alpha coefficients between 0.80 – 0.93 for the anxiety scale and 0.81 – 0.90 for 
the depression scale (28). Zigmond and Snaith support the HAD usefulness for repeated 
administration at sequential follow-up clinics (26). 
 
The Pain Coping Strategies Questionnaire (PCSQ) is a 44-item designed to measure coping 
strategies such as diverting attention, reinterpreting pain sensations, coping self-statements, 
ignoring pain sensations, praying or hoping, catastrophising and increased behavioural 
activities (29). Each of these seven subscales has a maximum score of 36 and a minimum 
score of zero, with higher scores indicating greater use of that particular coping strategy. 
Two additional subscales assess control over pain and ability to decrease pain, each of 
these items has a maximum score of six and minimum score of zero. Participants rate their 
thoughts and feelings about their pain using a seven-point scale ranging from 0 (never do) to 
  6 
6 (always do that). The PCSQ has demonstrated high internal consistency and higher test-
retest reliability when compared to other questionnaires including the multidimensional 
health locus of control questionnaire, the pain responses self-statements questionnaire and 
the pain responses coping statements questionnaire (30,31). 
 
Statistical analysis 
Repeated-measures ANOVA were performed to investigate changes in the variables 
between baseline, six-months and 12-months follow-ups. Assumption of sphericity was 
verified through Mauchly’s test. If the assumption of sphericity were violated, the degrees of 
freedom were corrected using Greenhouse-Geisser estimate of sphericity. 
Preliminary checks on assumptions for multiple regression, and regression diagnostics, were 
assessed. These included checks on multicollinearity of predictors (using tolerance 
statistics), checks for influential cases using Cook’s D, checks for independence of residuals 
using the Durbin-Watson statistic, checks for linearity of relationship and heteroscedasticity 
of residuals using a plot of standardised residuals against standardised predicted values. 
Histograms of residuals were checked to ensure normality of the residuals for each analysis 
also. None of these checks and diagnostics revealed any breach of assumptions for any of 
the hierarchical multiple regression analyses that were carried out. 
The 9 subscales of the PCSQ were subjected to a Principal Component Analysis for coping 
strategies subscales at the baseline stage. The main reasons for doing this were to avoid the 
higher likelihood of type I errors on a per predictor basis if regression analysis were 
conducted using individual subscales for the perceived coping strategies scale, and to 
produce independent factor scores summarising subscale variability thus avoiding 
multicollinearity issues that might arise if regression analysis using the PCSQ was 
conducted at a item based level. For both principal component analyses two factors were 
selected for varimax rotation, judged by visual inspection of a scree plot of eigenvalues. The 
plot of eigenvalues in each instance revealed a clear and marked jump in eigenvalues from 
factor three to factor two. In both component analyses the first factor was clearly identified 
with loadings on subscales relating to cognitive and behavioural strategies (CBS) for coping 
with pain, whilst the second factor was identified with loadings on subscales relating 
predominantly to an autonomous coping strategy (ACS), which broadly centred on the 
patient’s belief that they had the capacity to decrease their pain. Factor scores were 
calculated for each participant in the study using the regression method. 
For the hierarchical regression the demographic variables gender, age at time of implant and 
duration of pain prior to SCS treatment were entered in stage 1 of the regression analysis. 
This was considered particularly important in the case of the gender variable as any gender 
differences in predicted pain scores would imply the existence of heterogeneous 
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subsamples which might bias the estimate of the relationship between the psychological 
predictors entered into stage 2. In stage 2 of the analysis the psychological variables HAD 
anxiety, HAD depression, CBS, and ACS were entered. At both stages variables were 
entered using standard forced entry rather than stepwise techniques. 
Data is reported as mean ± standard error of mean (range). Statistical significance was 
judged at 5% level. Statistical tests were performed using the IBM Statistical Package for the 
Social Sciences (SPSS) software (version 19.0, SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
There were no statistically significant differences between patients who obtained ≥50% pain 
reduction during the SCS trial and those who had an unsuccessful SCS trial (p> 0.05). Fifty-
six patients (31 female and 25 male) were included in the final analysis. The mean age and 
duration of pain prior to SCS implant were 47.4 ± 1.5 years (24-70) and 8.2 ± 0.8 years (1-
25) respectively. Pain topography included buttock/leg/foot (n=25), back (n=6), arm/hand 
(n=5), head/neck (n=2) and multiple sites (n=18). Statistically significant improvements were 
observed for pain as measured with the VAS, disability, anxiety, depression, reinterpreting 
pain sensation, control over pain and ability to decrease pain (Table 1). 
 
Table 1. Sensory and psychological characteristics assessed 
Variable 
Baseline 
(n = 56) 
Six-months 
(n = 56) 
12-months 
(n = 56) 
Test statistic P 
Visual Analogue Scale 7.02 ± 0.18 (4.9-10) 5.04 ± 0.29 (0-9) 5.60 ± 0.30 (1-10) F(2, 110) = 23.53 < 0.001*** 
Oswestry Disability Index 52.18 ± 2.26 (16-88) 47.16 ± 2.67 (0-86) 46.48 ± 3.02 (0-84) F(2, 110) = 4.69 0.011* 
Hospital Anxiety and Depression 
     
 
HAD anxiety 9.11 ± 0.62 (2-20) 8.00 ± 0.55 (1-19) 8.16 ± 0.56 (0-20) F(1.76, 97.15) = 3.43 0.042* 
 
HAD depression 8.55 ± 0.61 (1-19) 6.98 ± 0.56 (0-17) 7.46 ± 0.63 (0-20) F(1.60, 88.29) = 5.39 0.010* 
Pain Coping Strategies Questionnaire 
     
 
Diverting attention 16.00 ± 0.97 (0-33) 16.36 ± 1.08 (0-36) 15.57 ± 1.06 (0-36) F(2, 110) = 0.46 0.633 
 
Reinterpreting pain sensation 8.10 ± 0.98 (0-34) 10.39 ± 1.17 (0-36) 8.69 ± 1.20 (0-36) F(2, 110) = 4.15 0.018* 
 
Catastrophising 15.25 ± 1.27 (0-36) 14.16 ± 1.24 (0-36) 13.94 ± 1.35 ( 0-36) F(2, 110) = 1.18 0.310 
 
Ignoring sensations 13.69 ± 1.09 (0-32) 14.00 ± 1.17 (0-36) 13.80 ± 1.14 (0-36) F(2, 110) = 0.06 0.938 
 
Praying or hoping 16.16 ± 1.09 (0-34) 15.21 ± 1.20 (0-36) 14.71 ± 1.18 (0-36) F(2, 110) = 1.61 0.205 
 
Coping self-statements 22.09 ± 0.95 (3-34) 22.23 ± 1.05 (3-36) 21.59 ± 0.98 (4-43) F(2, 110) = 0.30 0.739 
 
Increased behavioural activities 17.89 ± 0.91 (1-33) 18.77 ± 0.94 (0-36) 18.27 ± 0.96 (0-36) F(2, 110) = 0.48 0.616 
 
Control over pain 2.39 ± 0.19 (0-6) 3.14 ± 0.20 (0-6) 3.04 ± 0.18 (0-6) F(2, 110) = 7.98 0.001** 
 
Ability to decrease pain 2.08 ± 0.18 (0-5) 3.07 ± 0.21 (0-6) 2.75 ± 0.21 (0-6) F(2, 110) = 12.71 < 0.001*** 
Mean ± SEM (range) 
* p < 0.05; ** p < 0.005; *** p < 0.001 
 
At the 12-month follow-up, minimally important clinical changes (≥10% and <30%) in pain 
were experienced by 16 patients (28.6%), moderately important clinical changes (≥30% and 
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<50%) were obtained by five participants (8.9%) and substantial clinical changes (≥50%) 
were observed by 14 subjects (25%). 
 
Based on the ODI classification of disability, there was a decrease in the number of patients 
with disability scores between 21-80% and an increase in the proportion of patients rating 
their disability as minimal (Table 2). Minimal clinically important changes (> 10.5 points) from 
baseline were observed at 12-months for 19 patients (33.9%). 
 
Table 2. Classification of patients at the different assessments according to ODI 
and HAD questionnaires 
  Baseline Six-months 12-months 
  56 (100%) 56 (100%) 56 (100%) 
ODI 
   
0-20% Minimal disability 2 (3.6%) 6 (10.7%) 8 (14.3%) 
21-40% Moderate disability 13 (23.2%) 13 (23.2%) 12 (21.4%) 
41-60% Severe disability 24 (42.9%) 24 (42.9%) 22 (39.3%) 
61-80% Crippled 15 (26.8%) 12 (21.4%) 12 (21.4%) 
81-100% Bed-bound (exaggerating) 2 (3.6%) 1 (1.8%) 2 (3.6%) 
HAD Anxiety 
   
0-7 Normal 23 (41.1%) 26 (46.4%) 27 (48.2%) 
8-10 Borderline 13 (23.2%) 13 (23.2%) 12 (21.4%) 
≥11 Abnormal 20 (35.7%) 17 (30.4%) 17 (30.4%) 
HAD Depression 
   
0-7 Normal 25 (44.6%) 32 (57.1%) 32 (57.1%) 
8-10 Borderline 16 (28.6%) 12 (21.4%) 12 (21.4%) 
≥11 Abnormal 15 (26.8%) 12 (21.4%) 12 (21.4%) 
ODI, Oswestry Disability Index; HAD, Hospital Anxiety and Depression 
 
Predictors of pain reduction (Table 3) 
At stage 1 of the regression analysis the demographic variables did not significantly predict 
pain reduction at 12-months follow-up (R = 0.341, adjusted R-square = 0.116; F(3,53) = 
2.320, p = 0.086). With the addition of the psychological variables at stage 2 the overall 
model was significant (R = 0.498, adjusted R-square = 0.248; F(7,49) = 2.310, p = 0.041). 
The examination of the individual regression coefficients at stage 2 indicated that both the 
variables age at time of implant (Beta = 0.330, t(49) = 2.576, p = 0.013) and ACS factor 
score (Beta = 0.329, t(49) = 2.206, p = 0.032) were significant predictors of pain reduction 
following 12-months of SCS. 
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Table 3. Predictors of pain reduction 
    Baseline predictors of pain at 12-months 
Stage Predictor 
Standardised 
Coefficients 
(Beta) 
t P 
1 Sex -0.054 0.421 0.676 
 
Age at time of implant 0.324 2.452 0.018 
  Duration of pain prior to implant -0.186 -1.409 0.165 
2 Sex 0.023 0.184 0.855 
 
Age at time of implant 0.33 2.576 0.013 * 
 
Duration of pain prior to implant -0.213 -1.618 0.112 
 
HAD anxiety 0.23 1.373 0.176 
 
HAD depression -0.152 -0.83 0.411 
 
Cognitive and Behavioural 
Strategies Component 
0.009 0.072 0.943 
  
Autonomous Coping 
Component 
0.329 2.206 0.032 * 
  
Summary statistics 
  
Model 1: R=0.341, R2=0.116, F(3,53)=2.320, p=0.086 
    Model 2: R=0.498, R2=0.248, F(7,49)=2.310, p=0.041 * 
* p < 0.05 
 
Predictors of improvement in ODI scores (Table 4) 
Demographic variables entered at stage 1 of the regression analysis did not significantly 
predict ODI improvement at 12-months (R = 0.246, adjusted R-square = 0.061; F(3,53) = 
1.140, p = 0.341). The psychological predictors entered at stage 2 generated a significant 
model (R = 0.579, adjusted R-square = 0.336; F(7,49) = 3.538, p = 0.004). The examination 
of the individual regression coefficients at stage 2 showed that the variables duration of pain 
prior to implant (Beta = 0.320, t(49) = 2.583, p = 0.013) and HAD depression (Beta = 0.470, 
t(48) = 2.728, p = 0.009) were significant predictors of ODI reduction at 12-month follow-up. 
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Table 4. Predictors of improvement in ODI scores 
    Baseline predictors of ODI at 12-months 
Stage Predictor 
Standardised 
Coefficients 
(Beta) 
t P 
1 Sex -0.082 -0.615 0.541 
 
Age at time of implant -0.152 -1.117 0.269 
  Duration of pain prior to implant 0.212 1.556 0.126 
2 Sex -0.118 -0.987 0.328 
 
Age at time of implant -0.101 -0.841 0.404 
 
Duration of pain prior to implant 0.32 2.583 0.013 * 
 
HAD anxiety 0.028 0.176 0.861 
 
HAD depression 0.47 2.728 0.009 * 
 
Cognitive and Behavioural 
Strategies Component 
-0.087 -0.713 0.479 
  
Autonomous Coping 
Component 
-0.069 -0.489 0.627 
  
Summary statistics 
  
Model 1: R=0.246, R2=0.061, F(3,53)=1.140, p=0.341 
    Model 2: R=0.579, R2=0.336, F(7,49)=3.538, p=0.004 ** 
* p < 0.05; ** p < 0.005 
 
DISCUSSION 
This study demonstrates that SCS may provide statistically and clinically significant 
improvements in pain intensity and disability. Moreover, we observed that characteristics 
such as duration of pain prior to implant, age at time of implant and psychological 
characteristics including depression and autonomous coping (control over pain, ability to 
reduce pain and catastrophising) may impact on the outcome of SCS treatment based on 
pain intensity and disability. A recent study has found self-efficacy to impact on longer-term 
outcomes for SCS and depression and anxiety to have no significant impact (32). Previous 
studies have suggested similar concepts such as dispositional optimism and activity 
engagement aspect of acceptance as having an impact on reduction of perceived pain 
(33,34). These concepts describe a situation where patients do not allow pain to influence 
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every aspect of their lives. Self-efficacy, activity engagement and dispositional optimism can 
be likened to the autonomous coping factor (control over pain, ability to decrease pain and 
catastrophising) which was a significant factor in the current study. 
 
The autonomous coping factor which comprises the variables PCSQ control over pain, 
PCSQ ability to decrease pain and PCSQ catastrophising was predictive of pain reduction at 
12-months. This finding suggests that patients with increased perceived control over pain 
and ability to decrease pain alongside lower levels of catastrophising at baseline achieve 
greater reductions in pain following 12-months of SCS. High levels of catastrophising have 
previously been associated with increased pain intensity and poor treatment efficacy 
(13,14,35). Catastrophising alone has not been found to be a predictor SCS outcome in a 
recent study (36). The authors however stated that the lack of effect may have been due to 
the fact that almost all patients scored highly on the catastrophising scale. Catastrophising 
may increase pain intensity as patients maintain attention to their pain, which results in 
rumination and subsequent magnification of painful sensations (15). Catastrophising is also 
likely to interrelate with decreased perceptions of control over pain and ability to decrease 
pain. Control over pain and catastrophising have been reported as the most common 
psychological factors associated with the onset and continuation of chronic pain (13-16). 
 
Age at time of implant and duration of pain prior to implant were found to impact upon 
reductions in pain and ODI scores. Older participants obtained higher pain reduction and 
decreased disability following 12 months of SCS. When investigating postoperative pain 
reports, it was observed that younger patients report higher levels of pain (37,38). This may 
be related with the higher expectations younger individuals may have regarding a treatment. 
Nevertheless, contradictory findings have been reported with increased aged correlating 
negatively with percentage of pain change three months following SCS implantation (39) or 
no role of age in predicting the outcome of SCS (40). Additional research is required to 
further elucidate the potential role of age in SCS outcome. Previous research has observed 
duration of pain to influence reduction of pain following implantation of the SCS (40). We do 
not intend to suggest that SCS should come earlier in the pain treatment algorithm, as many 
patients will obtain good pain relief with more conservative treatments. However, the time 
spent assessing if a patient’s pain relief is satisfactory before proceeding to the next therapy 
should be decreased. 
 
The HAD depression score was found to be a significant predictor of reduction in disability at 
12-months but not a predictor of pain reduction. Previous studies have observed that 
depression is associated and impacts upon the experience and perception of pain 
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(10,16,41). However, we did not assess if the patients’ depression was state or trait. A ‘trait’ 
is recognised as a stable personality characteristic whereas a ‘state’ is a temporary 
personality feature in response to environmental circumstances. A recent systematic review 
of psychological characteristics impacting upon SCS suggested that depression associated 
with the onset of pain may not be a complete contraindication for SCS (12). However, pre-
morbid depression to the onset of pain may reduce the efficacy of SCS. An additional 
systematic review suggested that psychological factors such as somatization, depression, 
anxiety, and poor coping, are important predictors of poor outcome (42). 
 
There is good support for psychological factors affecting pain from both clinical work, 
neuroimaging, and also for SCS affecting pain at higher centres, including the anterior 
cingulate cortex (43-45). It is therefore reasonable to hypothesise that the pain relief 
achieved and psychological outcome are linked. Our focus was on constitutional 
psychological factors and their impact upon outcome. We can only conjecture as to the 
possible mechanisms. A neurochemical basis could explain less responsiveness due to 
greater diffuse noxious inhibitory control. A positive trial phase may occur due to an early 
placebo effect. The mechanisms of SCS however are still not completely understood 
(46,47). 
 
This study has limitations which could be addressed by future research. It has been reported 
that loss of analgesia may be experienced within 12-24 months following SCS implantation 
and therefore, it would be of interest to follow-up patients over a longer period. We did not 
collect information from the notes on other treatments implemented or changes in 
medication. At this centre oral rescue medication has been provided to the patients on an 
individual basis to cope with occasional flare-ups. Moreover, all of these patients have 
previously tried and failed more conservative options for the management of their pain. 
Therefore, systemic medication as well as other interventions that might have been 
undertaken during the study period would be occasional to cope with flare-ups and would 
therefore have limited impact in the results verified. Collecting information about the patients 
average daily use of SCS would also allow to produce a more comprehensive report on the 
patients pain relief profile and investigate associations between psychological characteristics 
and average usage of SCS. Twelve patients were lost to follow-up. All of the patients were 
contacted prior to a follow-up to attend a review clinic to assess if the SCS is working 
adequately and data collection would occur at this time. The patients who were lost to follow-
up were contacted several times to attend this clinic but failed to respond on all occasions. It 
would be beneficial to distinguish whether impacting psychological variables are state or trait 
as research investigating predictors of pain intensity in patients scheduled for elective 
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abdominal surgery found that whilst state anxiety was a significant predictor of pain intensity, 
trait anxiety was not (48). Trait depression may impact upon long-term efficacy of SCS but 
needs further investigation. State depression should not be considered as contraindicative 
for implantation as it may improve with successful SCS. We did not included patients with 
unrealistic expectations of the treatment and unrealistic beliefs surrounding their pain as 
assessed by a multidisciplinary team including a clinical psychologist. Beliefs and 
expectations are associated with psychological variables and the inclusion of these patients 
could potentially lead to clearer psychological predictors of pain relief. However, the 
inclusion of these patients is currently not recommended and would carry ethical concerns 
considering the invasiveness of therapy and unlikely patient benefit. 
 
In conclusion, this study has observed that psychological characteristics such as depression 
and autonomous coping strategies may influence and predict the long-term efficacy of SCS. 
Also age at time of implant and duration of pain prior to implant were found to impact upon 
SCS outcome. Support for patients with low autonomous coping strategies and long 
standing depression prior to implant may prove efficacious to long-term SCS outcome. 
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